GURUFOCUS.COM » STOCK LIST » USA » NYSE » Pfizer Inc (NYSE:PFE) » Definitions » ROE %
Switch to:

Pfizer ROE %

: 46.72% (As of Jun. 2022)
View and export this data going back to 1951. Start your Free Trial

ROE % is calculated as Net Income attributable to Common Stockholders (Net Income minus dividends to participating security holders) divided by its average Total Stockholders Equity over a certain period of time. Pfizer's annualized net income attributable to common stockholders for the quarter that ended in Jun. 2022 was $39,624 Mil. Pfizer's average Total Stockholders Equity over the quarter that ended in Jun. 2022 was $84,816 Mil. Therefore, Pfizer's annualized ROE % for the quarter that ended in Jun. 2022 was 46.72%.

The historical rank and industry rank for Pfizer's ROE % or its related term are showing as below:

PFE' s ROE % Range Over the Past 10 Years
Min: 10.23   Med: 17.2   Max: 37.33
Current: 37.33

During the past 13 years, Pfizer's highest ROE % was 37.33%. The lowest was 10.23%. And the median was 17.20%.

PFE's ROE % is ranked better than
96.5% of 1029 companies
in the Drug Manufacturers industry
Industry Median: 3.92 vs PFE: 37.33

Pfizer ROE % Historical Data

The historical data trend for Pfizer's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pfizer Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
ROE %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.57 16.56 25.33 14.49 31.30

Pfizer Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
ROE % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.10 44.72 17.75 39.41 46.72

Competitive Comparison

For the Drug Manufacturers - General subindustry, Pfizer's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Pfizer ROE % Distribution

For the Drug Manufacturers industry and Healthcare sector, Pfizer's ROE % distribution charts can be found below:

* The bar in red indicates where Pfizer's ROE % falls into.



Pfizer ROE % Calculation

Pfizer's annualized ROE % for the fiscal year that ended in Dec. 2021 is calculated as

ROE %=Net Income attributable to Common Stockholders (A: Dec. 2021 )/( (Total Stockholders Equity (A: Dec. 2020 )+Total Stockholders Equity (A: Dec. 2021 ))/ count )
=21979/( (63238+77201)/ 2 )
=21979/70219.5
=31.30 %

Pfizer's annualized ROE % for the quarter that ended in Jun. 2022 is calculated as

ROE %=Net Income attributable to Common Stockholders (Q: Jun. 2022 )/( (Total Stockholders Equity (Q: Mar. 2022 )+Total Stockholders Equity (Q: Jun. 2022 ))/ count )
=39624/( (82424+87208)/ 2 )
=39624/84816
=46.72 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income attributable to common stockholders of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income attributable to common stockholders data used here is four times the quarterly (Jun. 2022) net income attributable to common stockholders data. ROE % is displayed in the 30-year financial page.


Pfizer  (NYSE:PFE) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %**(Q: Jun. 2022 )
=Net Income/Total Stockholders Equity
=39624/84816
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(39624 / 110968)*(110968 / 189565.5)*(189565.5 / 84816)
=Net Margin %*Asset Turnover*Equity Multiplier
=35.71 %*0.5854*2.235
=ROA %*Equity Multiplier
=20.9 %*2.235
=46.72 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %**(Q: Jun. 2022 )
=Net Income/Total Stockholders Equity
=39624/84816
=(Net Income /Pre-Tax Income) * (Pre-Tax Income/Operating Income) * (Operating Income/Revenue) * (Revenue/Total Assets) * (Total Assets/Total Stockholders Equity)
= (39624 / 45788) * (45788 / 49636) * (49636 / 110968) * (110968 / 189565.5) * (189565.5 / 84816)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.8654 * 0.9225 * 44.73 % * 0.5854 * 2.235
=46.72 %

Note: The net income attributable to common stockholders data used here is four times the quarterly (Jun. 2022) net income attributable to common stockholders data. The Revenue data used here is four times the quarterly (Jun. 2022) revenue data. The same rule applies to Pre-Tax Income and Operating Income.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.


Be Aware

Net income attributable to common stockholders is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Pfizer ROE % Related Terms

Thank you for viewing the detailed overview of Pfizer's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Pfizer Business Description

Pfizer logo
Address
235 East 42nd Street, New York, NY, USA, 10017
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
Executives
Denton David M officer: Chief Financial Officer & EVP 1000 LOWE'S BOULEVARD MOORESVILLE NC 28117
Pao William officer: Executive Vice President C/O CORPORATE SECRETARY 235 EAST 42ND STREET NEW YORK NY 10017
Mcdermott Michael officer: Executive Vice President C/O PFIZER INC. CORPORATE SECRETARY 235 EAST 42ND STREET 235 EAST 42ND STREET NY 10017
Malik Aamir officer: Executive Vice President C/O PFIZER INC. CORPORATE SECRETARY 235 EAST 42ND STREET NEW YORK NY 10017
Carapezzi William R Jr officer: Executive Vice President 600 MOUNTAIN AVENUE MURRAY HILL NJ 07921
Sahni Payal officer: Executive Vice President ATTN: PFIZER CORP. SECRETARY 235 EAST 42ND ST. NEW YORK NY 10017
Desmond-hellmann Susan director 513 PARNASSUS AVENUE S126 SAN FRANCISCO CA 94143
Hockfield Susan director GENERAL ELECTRIC COMPANY 41 FARNSWORTH STREET BOSTON MA 02210
Damico Jennifer B. officer: SVP & Controller C/O PFIZER INC. CORPORATE SECRETARY 235 EAST 42ND STREET NEW YORK NY 10017
Quincey James director THE COCA-COLA COMPANY ONE COCA-COLA PLAZA ATLANTA GA 30313
Gottlieb Scott director MOLECULAR INSIGHT PHARMACEUTICALS 160 SECOND STREET CAMBRIDGE MA 02142
Fonseca Lidia officer: Executive Vice President 358 SOUTH MAIN STREET BURLINGTON NC 27215
Goettler Michael officer: Group President 1000 MYLAN BOULEVARD CANONSBURG PA 15317
Rogers Dawn officer: Executive Vice President 235 EAST 42ND STREET NEW YORK NY 10017
Littman Dan R. director ATTN: CORPORATE SECRETARY PFIZER INC. 235 E. 42ND ST NEW YORK NY 10017

Pfizer Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)